Human Cardiolipin IgM ELISA kit

CAT#: EA100916

Human Cardiolipin IgM ELISA kit



CNY 2,900.00


货期*
6周

规格
    • 1 x 96 wells

Product images

Specifications

Product Data
Description Human Cardiolipin IgM ELISA kit
Size 1 x 96 wells
Format 8x12 divisible strips
Assay Type Solid Phase Sandwich ELISA
Assay Length 3 hours
Signal Colorimetric
Sample Type Serum
Sample Volume 10 µl/well
Specificity This kit is used for quantitative detection human Cardiolipin IgM
Reactivity Human
Cross Reactivity There is no detectable cross-reactivity with other relevant proteins.
Interference No significant interference observed with available related molecules.
Components
  • 1. Microwell coated with Cardiolipin antigen: 12x8x1
  • 2. Sample Diluent: 1 bottle (ready to use): 22 ml
  • 3. Calibrator: 1 Vial (ready to use): 1ml
  • 4. Positive Control: 1 vial (ready to use): 1ml
  • 5. Negative Control: 1 vial (ready to use): 1ml
  • 6. Enzyme conjugate: 1 bottle (ready to use): 12ml
  • 7. TMB Substrate: 1 bottle (ready to use): 12ml
  • 8. Stop Solution: 1 bottle (ready to use): 12ml
  • 9. Wash concentrate 20X: 1 bottle: 25ml
Background Measurement of IgG, IgM and IgA cardiolipin autoantibodies (aCL) by EIA is the standard procedure for the detection of antiphospholipid antibodies (aPL) in patients with suspected antiphospholipid syndrome (APS). High aCL concentrations are associated with increased risk of venous and arterial thrombosis, recurrent pregnancy loss and thrombocytopenia. Patients with the anti-cardiolipin syndrome have one of the above clinical features and have antibodies to cardiolipin and/or a positive lupus anticoagulant test. The antibodies present to cardiolipin may be of the IgG, IgA, IgM isotypes. Testing for the various antibody isotypes to cardiolipin aids in diagnosis of the anti-phospholipid syndrome in patients with SLE or lupus-like disorders. Binding of aCL to CL in patients with autoimmune diseases is dependent on the presence of the cofactor beta-2-glycoprotein I (beta2-GPI); this binding is independent of beta-2-GPI in patients with infectious diseases (e.g., syphilis, tuberculosis). Recognition of the role of beta-2- GPI in the binding of aCL led to development of assay for direct measurement of beta-2-GPI autoantibodies using beta-2-GPI as antigen, allowing a clear distinction between beta-2-GPI autoantibodies and those that bind to CL alone.
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Customer Reviews 
Loading...